financetom
Business
financetom
/
Business
/
MOVES-Hidehiro Imatsu named president of Goldman Sachs Japan
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
MOVES-Hidehiro Imatsu named president of Goldman Sachs Japan
Apr 25, 2024 2:49 AM

TOKYO, April 25 (Reuters) - Goldman Sachs ( GS ) has

appointed Hidehiro Imatsu as president of its Japan unit, it

said in a release on Thursday.

Imatsu, who is based in Hong Kong, will relocate to Tokyo

and, as well as serving as president, will retain his current

roles as co-head of global interest rates product trading and

co-head of the Asia Pacific fixed income, currency and

commodities.

Imatsu takes the place of Masanori Mochida, who announced he

would retire last year after more than 38 years at the

investment bank.

Mochida is credited with leading Goldman Sachs' ( GS ) expansion in

Japan, where it has had a presence for 50 years.

Global investors have become increasingly enthused by

Japanese companies as long-awaited corporate governance changes

and rising profits have helped drive the Nikkei share

average to record highs this year.

"As international investors focus their attention on the

Japanese market and the country's biggest companies look to

expand their global reach, Goldman Sachs ( GS ) will continue to

provide the highest level of service to clients under its new

leadership in Japan," the company said.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
BRIEF-Generate Biomedicines Announces Pricing Of IPO Of 25 Million Shares Of Common Stock At $16.00 Per Share
BRIEF-Generate Biomedicines Announces Pricing Of IPO Of 25 Million Shares Of Common Stock At $16.00 Per Share
Mar 11, 2026
Feb 26 (Reuters) - * GENERATE BIOMEDICINES, INC. ANNOUNCES PRICING OF INITIAL PUBLIC OFFERING * GENERATE BIOMEDICINES- PRICING OF ITS INITIAL PUBLIC OFFERING OF 25,000,000 SHARES OF COMMON STOCK AT A PUBLIC OFFERING PRICE OF $16.00 PER SHARE. Source text: Further company coverage: [ ] ...
Drug developer Generate Biomedicines raises $400 million in US IPO
Drug developer Generate Biomedicines raises $400 million in US IPO
Mar 11, 2026
Feb 26 (Reuters) - Drug developer Generate Biomedicines said on Thursday that it raised $400 million in its U.S. initial public offering, pricing shares at $16 each. ...
PRESS DIGEST-Financial Times - February 27
PRESS DIGEST-Financial Times - February 27
Mar 11, 2026
Feb 27 (Reuters) - The following are the top stories in the Financial Times. Reuters has not verified these stories and does not vouch for their accuracy. Headlines - Paramount clinches Warner Bros deal after Netflix ( NFLX ) walks away - Jack Dorsey's Block to cut workforce by 'nearly half' as it leans on AI tools - Ocado (...
Exclusive-Venezuela suspends 19 oil, gas production-sharing contracts signed under Maduro, sources say
Exclusive-Venezuela suspends 19 oil, gas production-sharing contracts signed under Maduro, sources say
Mar 11, 2026
HOUSTON, Feb 26 (Reuters) - Venezuela's oil ministry has suspended 19 oil production-sharing contracts with private companies signed under the administration of President Nicolas Maduro, four sources with knowledge of the move told Reuters on Thursday. The suspension has had no impact on the country's oil and gas output so far, the sources said. State oil giant PDVSA is selling...
Copyright 2023-2026 - www.financetom.com All Rights Reserved